** Shares of Lumos Diagnostics LDX.AX more than double in value to A$0.080
** Stock posts its biggest intraday pct gain since July 2023
** Healthcare tech co signs U.S. distribution and supply agreement for FebriDx valued at up to $317 million
** FebriDx is a rapid point of care test that helps clinicians differentiate between bacterial and non-bacterial acute respiratory infections through a fingerstick blood sample
** Agreement signed with Hong Kong-headquartered PHASE Scientific International
** About 15.8 million shares change hands, compared with the 30-day average volume of 663,247
** YTD, shares up 108.6%
(Reporting by Nichiket Sunil in Bengaluru)
((Nichiket.Sunil@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.